Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This is a single center phase II trial designed to optimize a clinical platform of
lymphodepleting chemotherapy and T-cell suppression to promote the persistence, function, and
expansion of allogeneic natural killer (NK) cells in patients with recurrent ovarian,
fallopian tube, primary peritoneal cancer and advanced metastatic breast cancer.